Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Recruiting 3Unknown 2Withdrawn 1Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Neoplasms 47Breast Neoplasms 46Colorectal Neoplasms 28Prostatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 19Glioblastoma 19Pancreatic Neoplasms 17Melanoma 17Lung Neoplasms 17Neoplasm Metastasis 16Glioma 14Stomach Neoplasms 13Carcinoma, Hepatocellular 13Brain Neoplasms 13Ovarian Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Triple Negative Breast Neoplasms 10Multiple Myeloma 10Head and Neck Neoplasms 10Carcinoma, Renal Cell 10Lymphoma 9Uterine Cervical Neoplasms 7Rectal Neoplasms 7Hematologic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Sarcoma 6Leukemia 6

Interventions

imisopasem manganese 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Hypotension × Clear all
NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

MetaPhore Pharmaceuticals

Phase 1/2 Suspended
48 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡